Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...

The rise of GLP-1 drugs is a reminder that we must move beyond the equation of thinness as health and value. These drugs are not the answer to the deep-rooted cultural problem of fatphobia ...

Overview of Obesity Treatment MarketThe global Obesity Treatment Market is valued at USD 22.2 Billion in 2024 and is projected to reach a value of USD 194.1 Billion by 2035 at a CAGR (Compound Annual ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...

Last year she bought a compounding pharmacy's version of tirzepatide, paying about $470 monthly, and had lost more than 20 pounds when the FDA announced the ban on compounded weight-loss drugs.